Systemic antineoplastic drugs

The nurse reviews the results of all laboratory tests at the time they are reported. The primary health care provider is notified of the results before the administration of successive doses of an antineoplastic drug. If these tests indicate a severe depressant effect on the bone marrow or other test abnormalities, the primary health care provider may reduce the next drug dose or temporarily stop chemotherapy to allow the affected body systems to recover. 

Unit X discusses drugp that affect the immune system. The unit consists of two chapters immunologic agents and antineoplastic drugs. 

This chapter explores the development of biodegradable polyanhydride polymers as a local chemotherapeutic delivery system in brain tumor patients. In so doing, the authors detail the unique pharmacokinetic considerations inherent in CNS drug delivery, and the resultant advantages of local administration. Subsequent sections chronicle the development of biocompatible technologies, preclinical and clinical experience with polymer-based tumor treatments, and potential future advancements in local antineoplastic drug delivery. 

Connors, K. M. Monosov, A. Native-state method and system for determining viabihty and proliferative capacity of tissue in vitro and for evaluation of antineoplastic drugs. PCT Int. Appl. WO 9501455, 1995 Chem. Abstr. 1995, 722, 178367. 

Hon C-Y, Teschke K, Demers PA, Veimers S (2004) Antineoplastic drug contamination on the hands of employees working throughout the hospital medication system. Ann Occup Hyg 58(6) 761-770... 

There is an increased risk for bone marrow suppression when levamisole or hydroxyurea are administered witii other antineoplastic dni. Use of levamisole witii phenytoin increases die risk of phenytoin toxicity. Pegaspargase may alter drug response of the anticoagulants. When procarbazine is administered with other central nervous system (CNS) depressants, such as alcohol, antidepressants, antihistamines, opiates, or the sedatives, an additive CNS effect may be seen. Procarbazine may potentiate hypoglycemia when administered witii insulin or oral antidiabetic dru . ... 

Use antineoplastic, immunosuppressive, multiple sclerosis therapeutic, antiangiogenic, disease modifying drug, systemic lupus erythematosus therapeutic... 

---